For decades clinicians have been frustrated by the inability to successfully detoxify opiate addicted patients because opiate-based detoxification, one of the most effective means to achieving that goal, has been unavailable outside the very restrictive confines of narcotic treatment programs (NTPs). A new medication, buprenorphine, shows promise as an effective aid for opiate detoxification. However, little data have been generated for the shorter-term use of buprenorphine/naloxone for this indication. This protocol will compare the clinical utility of two dosage tapering regimens in buprenorphine/naloxone stabilized subjects for opiate detoxification.
Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.